Tang LQ, et al. - Whether or not a nedaplatin-based concurrent chemoradiotherapy regimen is non-inferior to a cisplatin-based regimen in patients with locoregional, stage II–IVB nasopharyngeal carcinoma was investigated herein. Compared with the nedaplatin group, a significantly higher frequency of grade 3 or 4 vomiting, nausea, and anorexia was observed in the cisplatin group. Furthermore, the cisplatin group vsersus nedaplatin group had a higher frequency of any grade or grade 3 or 4 late auditory or hearing toxicities. Overall, nedaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy for patients with locoregional, advanced nasopharyngeal carcinoma.